Genentech

Biocon Secures Global Launch Dates for Pebrilzo Following Settlement with Genentech

Biocon Limited secures global launch dates for biosimilar Pebrilzo after settling with Genentech. EU launch set for Q1 2027 and US for Q3 2028 for the cancer drug.

Biocon · 14 Oct 2026, 8:28 AM IST